Mednet Logo
HomeMedical OncologyQuestion

Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer?

1
1 Answers
Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic

Immunotherapy demonstrated great activity in treating metastatic MSI-H colorectal cancer (CheckMate 142 study, KEYNOTE-177 study, etc). There are now several small studies showing the activity of immunotherapy in early stage or locally advanced colorectal cancer.

The NICHE study enrolled 40 patients...

Register or Sign In to see full answer

Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer? | Mednet